A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

Launched by ARCUS BIOSCIENCES, INC. · Feb 25, 2021

Keywords

ClinConnect Summary

This clinical trial is investigating a new treatment called AB308, used together with another drug called zimberelimab (AB122), to see how safe it is and how well it works for people with advanced cancers, such as lung cancer, melanoma, and several others. This study is in its early stages, focusing on understanding how the combination of these drugs affects the body and if they can help manage these serious conditions. It is currently active but not recruiting new participants.

To be eligible for this study, participants must be at least 18 years old and able to give consent. They should have a good performance status, meaning they can carry out daily activities with little or no difficulty. However, individuals with recent major surgeries, certain autoimmune diseases, or who have received specific cancer treatments recently may not qualify. If someone decides to participate, they can expect close monitoring and support throughout the study to ensure their safety and well-being.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
• • Male or female participants ≥ 18 years of age (or age ≥ regionally approved age of consent for participation in investigational clinical studies) at the time of signing the informed consent.
• • Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
• • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
• • Adequate organ and marrow function
• Exclusion Criteria:
• • History of trauma or major surgery within 28 days prior to the first dose of study treatment.
• • Prior treatment with an anti-TIGIT antibody.
• • Any active or prior autoimmune disease that required treatment within 3 years of the first dose of study treatment.
• • Prior chemotherapy, targeted small-molecule therapy, immunotherapy, or biologic agents, or use of other investigational drugs within 28 days before first dose of study treatment.
• • Discontinued prior immunotherapy for immune related adverse events with a high severity.
• • NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.